Adage Capital Partners Gp, L.L.C. Janux Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,327,896 shares of JANX stock, worth $127 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
2,327,896
Previous 2,775,672
16.13%
Holding current value
$127 Million
Previous $105 Million
6.69%
% of portfolio
0.19%
Previous 0.2%
Shares
8 transactions
Others Institutions Holding JANX
# of Institutions
160Shares Held
37.2MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$499 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$162 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$98 Million0.04% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY1.56MShares$85.1 Million2.65% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.27B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...